Fredun Pharmaceuticals Ratios

Fredun Pharmaceuticals Ltd Ratios

The Fredun Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Fredun Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Fredun Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Fredun Pharmaceuticals Ltd (NSE: , BSE: 539730) is currently trading at ₹1678.55, with a market capitalization of ₹9.07B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Fredun Pharmaceuticals Ltd remains a key stock for fundamental analysis using Fredun Pharmaceuticals Ltd Ratios.

Fredun Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Fredun Pharmaceuticals Ltd P/E ratio currently stands at 15.72, making it one of the most tracked metrics in Fredun Pharmaceuticals Ltd Ratios.

Historically, the Fredun Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 15.72
• 2023: 21.58
• 2022: 33.90
• 2021: 81.15
• 2020: 91.80

The decline in Fredun Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Fredun Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.23.

Historical P/B trend:

• 2024: 2.23
• 2023: 2.77
• 2022: 3.66
• 2021: 5.96

Fredun Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Fredun Pharmaceuticals Ltd P/S ratio currently stands at 0.68, an important part of Fredun Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.68
• 2023: 0.97
• 2022: 1.34
• 2021: 2.31

A stable or declining Fredun Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Fredun Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Fredun Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Fredun Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Fredun Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Fredun Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Fredun Pharmaceuticals Ltd EV currently stands at ₹4.73B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 4.73B
• 2023: 4.4B
• 2022: 4.49B
• 2021: 5.65B

Fredun Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Fredun Pharmaceuticals Ltd EV/EBITDA ratio is currently 8.78, a key metric in Fredun Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 8.78
• 2023: 11.54
• 2022: 16.05
• 2021: 40.67

Stable Fredun Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Fredun Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Fredun Pharmaceuticals Ltd D/E ratio is currently 1.19, reflecting leverage and financial stability.

Historical D/E:

• 2024: 1.19
• 2023: 0.87
• 2022: 0.90
• 2021: 0.78

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Fredun Pharmaceuticals Ltd ROE currently stands at 15.02%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.02
• 2023: 14.34
• 2022: 13.14
• 2021: 11.40

Fredun Pharmaceuticals Ltd maintains stable profitability levels.

Fredun Pharmaceuticals Ltd Ratios Analysis Summary

The Fredun Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Fredun Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Fredun Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.